Medpace EVP Susan E. Burwig sells 20,000 shares

The option had vested in full on October 27, 2025, and its reported post-exercise balance was zero.

Rhea-AI Filing Summary

Susan E. Burwig, Medpace Holdings, Inc.’s Executive Vice President, Operations, exercised options for 328 common shares at $166.73 per share on October 26, 2026. She sold 16,060 common shares that day and 3,940 on October 27, 2026, at $677 per share. The sales were effected pursuant to a limit order she placed during an open window period; no Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider BURWIG SUSAN E

Role Exec. VP, Operations

Sold 20,000 shs ($13.54M)

Approx. gross sale proceeds $13.54M

Approx. exercise cost $55K

Type	Security	Shares	Price	Value
Sale	Common Stock F1	3,940	$677.00	$2.67M
Exercise	Employee Stock Option (Right to Buy) F2	328	$0.00	$0.00
Sale	Common Stock F1	16,060	$677.00	$10.87M
Exercise	Common Stock	328	$166.73	$55K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 54,012 shares (Direct)

Footnotes (2)

1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. F2. The option vested in full on October 27, 2025.

Key Figures

Common shares sold: 16,060 shares Sale price: $677 per share Common shares sold: 3,940 shares +3 more

6 metrics

Common shares sold 16,060 shares October 26, 2026

Sale price $677 per share Sales on October 26 and October 27, 2026

Common shares sold 3,940 shares October 27, 2026

Common shares acquired through option exercise 328 shares October 26, 2026

Option exercise price $166.73 per share October 26, 2026

Reported option balance following exercise 0 options October 26, 2026

Key Terms

limit order, open window period, Employee Stock Option (Right to Buy), vested in full

4 terms

limit order financial

"effected pursuant to a limit order"

A limit order is an instruction to buy or sell a stock only at a specific price or better, giving you control over the exact price you pay or receive. It matters to investors because it acts like a price guard—similar to setting a maximum you’ll pay for an item at a store—so you avoid unexpected prices, though the trade may not happen if the market never reaches your limit.

open window period financial

"during an open window period"

Employee Stock Option (Right to Buy) financial

"Employee Stock Option (Right to Buy)"

vested in full financial

"The option vested in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MEDP shares did Susan E. Burwig sell, and at what price?

Susan E. Burwig sold 16,060 common shares on October 26, 2026, and 3,940 on October 27, 2026, at $677 per share on both dates. The sales were effected pursuant to a limit order she placed during an open window period.

What MEDP stock options did Susan E. Burwig exercise?

Susan E. Burwig exercised options covering 328 common shares on October 26, 2026, at an exercise price of $166.73 per share. The option had vested in full on October 27, 2025, and the reported post-exercise option balance was zero.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 04:23 PM EDT Accepted by SEC EDGAR 10/28/2026 - 04:23 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OHIO 45227

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/26/2026		S(1)		16,060	D	$677	57,624	D
Common Stock	10/26/2026		M		328	A	$166.73	57,952	D
Common Stock	10/27/2026		S(1)		3,940	D	$677	54,012	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$166.73	10/26/2026		M			328	(2)	10/27/2026	Common Stock	328	$0	0	D

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The option vested in full on October 27, 2025.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)